Brief: Panbela Announces Preliminary Safety Analysis For Aspire Trial
10/07/2023 13:53
Panbela Therapeutics Inc PBLA.O :
* PANBELA ANNOUNCES PRELIMINARY SAFETY ANALYSIS FOR ASPIRE
TRIAL
* PANBELA THERAPEUTICS INC - NO SAFETY CONCERNS WERE
IDENTIFIED
AND DSMB'S RECOMMENDATION IS TO PROCEED WITHOUT MODIFICATION TO
ASPIRE TRIAL
* PANBELA THERAPEUTICS INC - LOOKING FORWARD TO INTERIM
ANALYSIS
OF TRIAL IN EARLY 2024
* PANBELA THERAPEUTICS - INDEPENDENT DSMB OF PHASE III
ASPIRE
CLINICAL TRIAL COMPLETED PRE-SPECIFIED REVIEW OF SAFETY DATA FOR
TREATED PATIENTS IN TRIAL
Source text for Eikon: ID:nGNXcR9V5
Further company coverage: PBLA.O
Recent news on Panbela Therapeutics
See all newsBrief: Panbela Therapeutics Announces Third Independent Safety Review Of Phase 3 Aspire Clinical Trial DSMB Recommended Continuation With No Trial Modification
Brief: Nasdaq Notifies Panbela Therapeutics Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Brief: Panbela Announces Pricing of Approximately $9 Mln Public Offering
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Brief: Panbela Therapeutics Announces Exercise Of Warrants And Issuance Of New Warrants